These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11934227)

  • 1. Targeting vaccines to dendritic cells.
    Foged C; Sundblad A; Hovgaard L
    Pharm Res; 2002 Mar; 19(3):229-38. PubMed ID: 11934227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting dendritic cells for priming cellular immune responses.
    Gogolák P; Réthi B; Hajas G; Rajnavölgyi E
    J Mol Recognit; 2003; 16(5):299-317. PubMed ID: 14523943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routing dependent immune responses after experimental R848-adjuvated vaccination.
    van Aalst S; Jansen MAA; Ludwig IS; van der Zee R; van Eden W; Broere F
    Vaccine; 2018 Mar; 36(11):1405-1413. PubMed ID: 29409680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.
    Leleux J; Atalis A; Roy K
    J Control Release; 2015 Dec; 219():610-621. PubMed ID: 26489733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities and challenges of the pulmonary route for vaccination.
    Blank F; Stumbles P; von Garnier C
    Expert Opin Drug Deliv; 2011 May; 8(5):547-63. PubMed ID: 21438741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses.
    Tesfaye DY; Gudjonsson A; Bogen B; Fossum E
    Front Immunol; 2019; 10():1529. PubMed ID: 31333661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New generation of dendritic cell vaccines.
    Radford KJ; Caminschi I
    Hum Vaccin Immunother; 2013 Feb; 9(2):259-64. PubMed ID: 23291951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization to enhanced green fluorescence protein minor histocompatibility antigen by gene transduction into dendritic cells and peritoneal exudate macrophages.
    Satoh E; Li XK; Hara Y; Ogata K; Guo L; Kitazawa Y; Funeshima-Fuji N; Satoh T; Miyagi T; Sugiura W; Yamamoto N; Teramoto K; Arii S; Kimura H
    Transpl Immunol; 2007 Nov; 18(2):73-84. PubMed ID: 18005848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells.
    Chen BY; Zhou G; Li QL; Lu JS; Shi DY; Pang XB; Zhou XW; Yu YZ; Huang PT
    Immunol Lett; 2017 Oct; 190():118-124. PubMed ID: 28802641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM; Corthésy B; Merkle HP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Strategies for Mucosal Vaccination.
    Longet S; Lundahl MLE; Lavelle EC
    Bioconjug Chem; 2018 Mar; 29(3):613-623. PubMed ID: 29300463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dendritic cells of mucosa and skin: "recruited for vaccination"].
    Le Borgne M; Dubois B; Kaiserlian D
    Med Sci (Paris); 2007 Oct; 23(10):819-25. PubMed ID: 17937889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
    van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
    Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells, new tools for vaccination.
    Colino J; Snapper CM
    Microbes Infect; 2003 Apr; 5(4):311-9. PubMed ID: 12706444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor.
    Eriksson K; Sun JB; Nordström I; Fredriksson M; Lindblad M; Li BL; Holmgren J
    Eur J Immunol; 2004 May; 34(5):1272-81. PubMed ID: 15114660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Functional Properties of Neonatal Dendritic Cells: A Doorway to Enhance Vaccine Effectiveness?
    Papaioannou NE; Pasztoi M; Schraml BU
    Front Immunol; 2018; 9():3123. PubMed ID: 30687326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fully mobilizing host defense: building better vaccines.
    Raychaudhuri S; Rock KL
    Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Particle-based vaccines for transcutaneous vaccination.
    Combadière B; Mahé B
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):293-315. PubMed ID: 17915323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD11b+ DCs rediscovered: implications for vaccination.
    Ginhoux F; Schlitzer A
    Expert Rev Vaccines; 2014 Apr; 13(4):445-7. PubMed ID: 24564769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.